Every patient receives a comprehensive evaluation, including:

• Medical history and current medications

• Review of weight-related health conditions

• Assessment of metabolic, hormonal, and lifestyle factors

• Discussion of potential risks, benefits, and alternatives

We also assess wellness and aesthetic goals, helping patients understand how medical weight management can support energy, mobility, skin health, and overall appearance.

Many patients seeking weight management have co-existing health conditions, including:

• Type 2 diabetes

• Hypertension

• Thyroid or hormonal disorders

• Cardiovascular risk factors

We monitor these alongside wellness and aesthetic interventions, ensuring holistic support. Nutritional planning, IV therapy, and aesthetic treatments are integrated into the care plan, allowing health improvement and physical confidence to progress together.

Wegovy® is administered within a clinically supervised programme to ensure safety and effectiveness. Our structured approach includes:

• Gradual dose escalation with careful monitoring

• Regular follow-up consultations with the team

• Ongoing assessment of progress and side effects

• Integration with lifestyle and nutritional guidance

This approach ensures safe, evidence-based, and comprehensive results, supporting long-term health, vitality, and confidence.

Every patient responds differently to treatment. Our team emphasises:

• Safe, responsible use of medication

• Combination with lifestyle measures and wellness interventions

• Gradual, sustainable improvements in weight, metabolism, and appearance

Expectations are clear, personalised, and medically informed, encompassing both health outcomes and aesthetic goals.

Our team is committed to:

• Responsible prescribing and supervision

• Integrated wellness and aesthetic care

• Patient-centred, safe, and supportive treatment

• Coordinated care across all services

All Wegovy® treatment and related interventions are supervised by our expert team, ensuring health, wellness, and aesthetic goals are addressed together.

A comprehensive initial consultation with Dr. Olga is $300.00.

Medication typically costs around NZ$460–$500 per month.

Wegovy® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight and that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off. Wegovy® is a prescription medication. Ask your doctor if Wegovy® is is right for you. Use strictly as directed. If you experience side effects, see your doctor, pharmacist or healthcare professional.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088. Wegovy® FlexTouch® (semaglutide solution for injection). Available in the following dose forms: 0.25 mg (0.68 mg/mL), 0.5 mg (1.34 mg/mL), 1.0 mg (1.34 mg/mL), 1.7 mg (2.27 mg/mL) and 2.4 mg (3.2 mg/mL). Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adult patients with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity; in adolescents ages 12 years and above with initial obesity\* and body weight above 60 kg (\* obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) – refer to full datasheet); as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a BMI ≥27 kg/m2, and without established Type 1 or Type 2 diabetes. Treatment with Wegovy® should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. Dosage and administration: Administered subcutaneously once weekly at any time of day, with or without meals; starting dose 0.25 mg; increase to a maintenance dose of 2.4 mg over a 16-week period at 4 weekly intervals. In case of significant gastrointestinal symptoms, consider delaying dose escalation until symptoms have improved. If patients do not tolerate the 2.4 mg dose, the dose can be decreased to 1.7 mg weekly. Patients should re-escalate to the 2.4 mg dose if tolerated. Doses higher than 2.4 mg are not recommended. Must not be administered intravenously or intramuscularly. Contraindications\:Hypersensitivity to semaglutide or any of its excipients. Warnings and precautions: Consider the risk of aspiration during general anaesthesia or deep sedation; dehydration in relation to gastrointestinal side effects in patients with impaired renal function may cause deterioration in renal function; there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure. Inform patients of the characteristic symptoms of acute pancreatitis, and discontinue if suspected; do not restart if confirmed. Exercise caution in patients with a history of pancreatitis. Not studied in patients: treated with other products for weight management; with Type 1 diabetes; with congestive heart failure New York Heart Association (NYHA) class IV. Limited experience in patients: aged 85 years or more; with inflammatory bowel disease; with diabetic gastroparesis; with severe renal impairment; with severe hepatic impairment. Must not be used as a substitute for insulin. Should not be used in combination with other GLP-1 products. Treatment in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The addition of Wegovy® in patients treated with insulin has not been evaluated. Patients with a history of diabetic retinopathy should be monitored for worsening. Not recommended for patients with uncontrolled or unstable diabetic retinopathy. When initiating treatment of semaglutide in patients treated with warfarin or other coumarin derivatives, frequent monitoring of INR is recommended. Pregnancy Category D. Not for use during pregnancy or breast-feeding. Interactions: Semaglutide delays gastric emptying, use with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption. Undesirable effects: Very Common (≥10%): nausea, vomiting, diarrhoea, constipation, abdominal pain, headache, fatigue. Common (≥1 to <10%): gastritis, gastroesophageal reflux disease, dyspepsia, eructation, flatulence, abdominal distension, dry mouth, dizziness, dysgeusia, dysaesthesia, cholelithiasis, hair loss, injection site reactions; in patients with Type 2 diabetes: hypoglycaemia, diabetic retinopathy. (April 2025)